Bloodstream infections, also known as bacteremia or septicemia, occur when bacteria or other pathogens enter the bloodstream, leading to a systemic infection. These infections can arise from various sources, such as untreated wounds, surgical procedures, urinary tract infections, or infections in other parts of the body. Symptoms of bloodstream infections may include fever, chills, rapid heartbeat, low blood pressure, and general malaise. Severe cases can progress to sepsis, a life-threatening condition that can lead to organ failure. Diagnosis typically involves blood cultures, which identify the specific pathogen causing the infection. Early detection and appropriate treatment with antibiotics are crucial to preventing the spread of the infection and minimizing complications. Risk factors for bloodstream infections include weakened immune systems, chronic illnesses, invasive medical procedures, and the presence of medical devices like catheters. Preventive measures include proper hygiene, infection control practices in healthcare settings, and prompt treatment of infections at their source. Bloodstream infections pose a significant health threat, requiring prompt medical attention and intervention to ensure optimal outcomes for affected individuals.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States